Contact this trialFirst, we need to learn more about you.
CAR T-cell Therapy
CYAD-02 for Leukemia/Preleukemia
Recruiting3 awardsPhase 1
Fairway, Kansas
This trial tests CYAD-02, a cell-based treatment, in patients with relapsed or refractory AML or MDS who haven't responded to standard treatments. Patients receive mild chemotherapy first, followed by CYAD-02 infusions to target cancer cells. If effective, they may receive additional doses.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service